Neuspera Medical, Inc. news

Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder (OAB) for patients with urinary urgency incontinence (UUI) symptoms. The system is

Neuspera Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of industry veterans Melissa Farina as Chief Financial Officer and Steven Siegel, MD, as Chief Medical Officer. Farina and Siegel have joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). The company presented initial, positive results from the feasibility phase at the A

Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures.  Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors.  Returning Series A and Serie

Neuspera Medical Inc., a clinical stage, private, venture capital backed neuromodulation company, announced the receipt of an Investigational Device Exemption (IDE) from the FDA – enabling the company to conduct the first long-term clinical trial of its ultra-miniaturized neuromodulation platform. An MRI Conditional version of Neuspera’s wirelessly powered implant designed for use as a sacral nerve stimulator will be studied for treatment of Urinary Urge Incontinence (UUI) –